Department of Clinical Immunology and Bone Marrow Transplantation, Great Ormond Street Hospital National Health Service Trust, London, UK.
J Clin Immunol. 2015 May;35(4):366-72. doi: 10.1007/s10875-015-0158-0. Epub 2015 Apr 15.
Adenosine deaminase (ADA) deficiency is a systemic disorder of purine metabolism. Deficiency of the purine salvage enzyme ADA leads to the build-up of the toxic metabolites, deoxyadenosine triphosphate and deoxyadenosine. ADA is ubiquitously expressed in all tissues of the body but most profoundly affects lymphocyte development and function leading to severe combined immunodeficiency (SCID). Unlike most other forms of SCID, ADA deficiency also results in non-immunologic manifestations. Associations between ADA deficiency and sensorineural hearing loss, behavioural abnormalities, non-infectious pulmonary disease and skeletal dysplasia are all recognised, and affect the long term outcome for these patients. Identification of new non-immunological manifestations and clinical presentations of ADA deficiency is essential to allow early optimisation of supportive care.
Here we report four patients with ADA deficiency whose presenting feature was haemolytic uremic syndrome (HUS). 3 of 4 patients were diagnosed with ADA deficiency only after developing HUS, and one diagnosis was made post mortem, after a sibling was diagnosed with SCID. Shiga-toxigenic organisms were not isolated from any of the patients. 2 patients made a good recovery from their HUS with supportive treatment and initiation of PEG-ADA. Both remain well on enzyme replacement with mild or no residual renal impairment.
Clinicians should be aware of this previously unreported non-immunologic manifestation of ADA deficiency.
腺苷脱氨酶(ADA)缺乏症是一种嘌呤代谢的全身性疾病。嘌呤补救酶 ADA 的缺乏导致有毒代谢物脱氧腺苷三磷酸和脱氧腺苷的积累。ADA 在体内所有组织中广泛表达,但对淋巴细胞的发育和功能影响最大,导致严重联合免疫缺陷(SCID)。与大多数其他形式的 SCID 不同,ADA 缺乏症还会导致非免疫表现。ADA 缺乏症与感觉神经性听力损失、行为异常、非传染性肺部疾病和骨骼发育不良之间的关联已得到公认,并影响这些患者的长期预后。识别 ADA 缺乏症的新的非免疫表现和临床特征对于早期优化支持性护理至关重要。
我们在此报告了 4 例以溶血性尿毒综合征(HUS)为首发表现的 ADA 缺乏症患者。4 例患者中有 3 例在发生 HUS 后才被诊断为 ADA 缺乏症,1 例在 1 名同胞被诊断为 SCID 后通过尸检确诊。未从任何患者中分离出志贺毒素产生菌。2 例患者在接受支持治疗和 PEG-ADA 治疗后,HUS 恢复良好。2 例患者均通过酶替代治疗,肾功能轻度受损或无残留肾功能受损,病情稳定。
临床医生应意识到 ADA 缺乏症以前未被报道的这种非免疫表现。